Device Week, 7 August 2020: Brexit, COVID-19 & NHS Reform Augur Big 12 Months For UK Medtech
Executive Summary
In this Device Week, Ashley Yeo asks PB Consulting managing director Dan Jones about the adjustments needed by UK medtechs as they face a confluence of change brought about by Brexit, COVID-19 and NHS reform, at a time when the MHRA is also coming under increased scrutiny.
The UK medical devices industry has been in a state of constant flux for many years, but the challenges it now faces are now bigger than ever, given the need to adjust to Brexit and a possible EU deal, COVID-19 and the stopping and restarting of planned care, and NHS reform and the integrated care systems (ICS) program, as well as scrutiny of the MHRA. These themes have all risen to the top of the agenda at the same time.
In this podcast, PB Consulting managing director Dan Jones gives his views on:
-
The sheer size of the challenge presented by these changes (above) that are all coming to a head concurrently (00:36);
-
The end of the Brexit transition period and what benefits are to be derived by UK medtech from being outside the EU (5:45);
-
Brexit and UK continuity of supply of medtech products (9:35);
-
The MHRA under pressure – over COVID-19 and the Cumberlege report. What global role can the UK regulator fulfil outside the EU? (12:26);
-
The likely timetable for the UK's Medicines and Medical Devices legislation – does it confer the appropriate level of power on the government? Secondary legislation coming to the fore (17:00);
-
NHS planning: among medtech clients’ top concerns in the current environment (22:46); and
-
The immediate future for PB Consulting’s political and medtech knowledge and business advisory service (25:55).